7 Dividend-Paying Stocks To Add To Your Income Portfolio In 2024
I believe that 2024 will be good for equities. Potential rate cuts are a big impending catalyst.
GSK gets shot in arm from upgrade, AstraZeneca mixed reviews after China deal
GSK PLC (LSE:GSK, NYSE:GSK) shares got a shot in the arm this morning after Jefferies took a more positive view of the pharmaceuticals giant. The US investment bank upgraded its rating to ‘buy' fro...
C4X Discovery receives $11m AstraZeneca milestone payment
C4X Discovery Holdings PLC (AIM:C4XD) has reached what has been described as a "significant milestone" after receiving an $11 million payment under its $402 million deal with pharma giant AstraZene...
AstraZeneca, Sanofi's RSV infant shots approved in China
AstraZeneca and Sanofi's respiratory syncytial virus (RSV) immunization for infants has been approved in China, the London-listed drugmaker said on Tuesday.
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
Astrazeneca (AZN) closed the most recent trading day at $67.35, moving +0.07% from the previous trading session.
Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, Astrazeneca (AZN) closed at $67.35, indicating a +1.28% shift from the previous trading day.
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.
AstraZeneca to buy Chinese drug firm in billion dollar deal
AstraZeneca PLC (LSE:AZN) is set to acquire Gracell Biotechnologies, the Chinese company specialising in innovative cancer and autoimmune disease treatments, for US$1.2 billion The US$2 per share a...
Yes Virginia, There Is a Santa Claus Rally
The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.
Acquisitions Push 2 Pharma Stocks in Opposite Directions
Pharmaceutical giants AstraZeneca plc (NASDAQ:AZN) and Bristol-Myers Squibb Co (NYSE:BMY) announced new acquisitions today.
AstraZeneca to Acquire China's Gracell in $1.2 Billion Deal to Further Cell Therapy Goals
AstraZeneca's acquisition of Gracell is expected to close in the first quarter of 2024.
Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment
Ionis Pharmaceuticals IONS, +1.61% and AstraZeneca's AZN, +0.79% Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of a rare genetic disease.
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
The anti-obesity drug market could be a significant growth opportunity for healthcare companies. Eli Lilly and Novo Nordisk are the big names in the market today, but there could soon be others.
Lloyds, AstraZeneca, BATs, Rolls-Royce: What's on the menu for 2024?
For investors, the focus in 2024 will be on navigating a year expected to be split into distinct halves. That, at least, is the conclusion of Liberum, the boutique investment bank, in assessing the...
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Astrazeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day.
Related Companies